The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Azacitidine 25 mg/ml powder for suspension for injection

Clonmel Healthcare LtdPA0126/362/001

Main Information

Trade NameAzacitidine 25 mg/ml powder for suspension for injection
Active SubstancesAzacitidine
Dosage FormPowder for suspension for injection
Licence HolderClonmel Healthcare Ltd
Licence NumberPA0126/362/001

Group Information

ATC CodeL01BC07 azacitidine


License statusAuthorised
Licence Issued29/07/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back